golnerminogene pradenovec
Gene therapyexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Jan 10, 2003 (NCT00051480)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108704 ↗
Also known as
- adgv egr.tnf.11d
- golnerminogene pradenovec
- tnferade
- tnferade
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01048151 | Phase 1 | Jan 12, 2010 | GenVec, National Institutes of Health (NIH) |
| NCT00496535 | Phase 1/Phase 2 (Phase 2) | Jul 2, 2007 | GenVec |
| NCT00496236 | Phase 1/Phase 2 (Phase 2) | Jun 28, 2007 | GenVec, University of Chicago |
| NCT00261404 | Phase 2 | Dec 2, 2005 | GenVec |
| NCT00137878 | Phase 2 | Aug 26, 2005 | GenVec |
| NCT00051467 | Phase 3 | Jan 10, 2003 | GenVec |
| NCT00051480 | Phase 2 | Jan 10, 2003 | GenVec |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GenVec | For profit | 7 | 7 | 3 | 2003 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1